Prognostic impact of concomitant pH-regulating drugs in patients with non-small cell lung cancer receiving epidermal growth factor receptor tyrosine kinase inhibitors: the Tokushukai REAl-world Data project 01-S1

Uryu, Kiyoaki; Imamura, Yoshinori; Shimoyama, Rai; Mase, Takahiro; Fujimura, Yoshiaki; Hayashi, Maki; Ohtaki, Megu; Otani, Keiko; Hibino, Makoto; Horiuchi, Shigeto; Fukui, Tomoya; Fukai, Ryuta; Chihara, Yusuke; Iwase, Akihiko; Yamada, Noriko; Tamura, Yukihiro; Harada, Hiromasa; Shinozaki, Nobuaki; Shimada, Toyoshi; Tsuya, Asuka; Fukuoka, Masahiro; Minami, Hironobu

doi:10.1007/s00280-024-04666-4

Cancer Chemother Pharmacol

2024

DOI: 10.1007/s00280-024-04666-4

|View full text |Cite

Prognostic impact of concomitant pH-regulating drugs in patients with non-small cell lung cancer receiving epidermal growth factor receptor tyrosine kinase inhibitors: the Tokushukai REAl-world Data project 01-S1

Kiyoaki Uryu,

Yoshinori Imamura,

Rai Shimoyama

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2025

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Risks of anti-Helicobacter therapy and long-term therapy with antisecretory drugs

Kotelevets

2025

World J Gastroenterol

View full text Add to dashboard Cite

Helicobacter pylori (H. pylori ) infection has a protective effect on gastroesophageal reflux disease (GERD). Both of these diseases have a very high incidence and prevalence. As a result, GERD often recurs after anti-Helicobacter therapy. The problem of effective treatment of H. pylori infection and GERD is that the main groups of drugs [proton pump inhibitors (PPIs) and potassium-competitive acid blockers] have the possibility of side effects with use. Such supposed side effects have no evidence in randomized controlled trials that comply with the principles of evidence-based medicine. Morphological changes in the gastric mucosa after long-term use of antisecretory drugs should be considered as compensatory mechanisms of sanogenesis. The greatest concern for doctors who treat patients with antisecretory drugs is the risk of gastric carcinogenesis. This article presents an analysis of morphological and pathophysiological changes that occur after long-term use of antisecretory drugs (PPIs). Hypertrophy (hyperplasia) of G cells, enterochromaffin-like cells and possible fundic gland polyps (hyperplasia) are compensatory mechanisms of sanogenesis during long-term treatment with PPIs. These mechanisms are of primary importance for rehabilitation and prevention of complications in patients with GERD, non-steroidal anti-inflammatory drugs-gastropathy and other diseases during long-term treatment with PPIs. Understanding the pathophysiological and morphological mechanisms of compensation and adaptation, the mechanisms of sanogenesis and carcinogenesis will increase the number of indications for long-term use of PPIs with a high level of efficiency and safety of treatment. In addition, understanding the pathophysiological and morphological mechanisms of compensation and adaptation, the mechanisms of sanogenesis will allow us to forecast the side effects of long-term use of potassium-competitive acid blockers.

show abstract

Risks of anti-Helicobacter therapy and long-term therapy with antisecretory drugs

Kotelevets

2025

World J Gastroenterol

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Prognostic impact of concomitant pH-regulating drugs in patients with non-small cell lung cancer receiving epidermal growth factor receptor tyrosine kinase inhibitors: the Tokushukai REAl-world Data project 01-S1

Cited by 1 publication

References 44 publications

Risks of anti-Helicobacter therapy and long-term therapy with antisecretory drugs

Risks of anti-Helicobacter therapy and long-term therapy with antisecretory drugs

Contact Info

Product

Resources

About